Applied DNA Sciences Changes Ticker Symbol to BNBX Reflecting Digital Asset Strategy

Applied DNA Sciences is changing its ticker symbol from "APDN" to "BNBX" on the Nasdaq Capital Market on October 7, 2025. The new ticker symbol reflects the company's strategic commitment to a BNB-based treasury strategy, aiming to optimize yield generation and token accumulation within the Binance ecosystem. The company plans to integrate actively managed decentralized finance protocols and Binance ecosystem-specific strategies to enhance capital efficiency, liquidity resilience, and exposure to digital asset upside. No action is required from stockholders, and the common stock will continue to be listed on Nasdaq with an unchanged CUSIP number.

Applied DNA Sciences, Inc. (NASDAQ: APDN) has announced a significant change in its ticker symbol. Effective October 7, 2025, the company's ticker on the Nasdaq Capital Market will change from "APDN" to "BNBX" Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy^[1]. This change underscores the company's strategic commitment to a Binance Coin (BNB)-based treasury strategy, aiming to optimize yield generation and token accumulation within the Binance ecosystem.

The new ticker symbol "BNBX" reflects the company's strategic shift towards integrating actively managed decentralized finance (DeFi) protocols and Binance ecosystem-specific strategies. These efforts are designed to enhance capital efficiency, liquidity resilience, and exposure to digital asset upside. The company plans to deploy a differentiated approach to treasury management, leveraging the Binance ecosystem to maximize the benefits of its digital asset holdings.

No action is required from the company's stockholders regarding the ticker symbol change. The common stock will continue to be listed on Nasdaq, and the CUSIP number will remain unchanged. Investors are advised to update their records to reflect the new ticker symbol.

Applied DNA Sciences is a biotechnology company that executes a yield-focused BNB digital asset treasury strategy while also commercializing proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.